ArticleAntimicrobial agents and chemotherapy2016
Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Article
- Identification of natural TLR4 modulators through network pharmacology and molecular modeling in SARS-CoV-2Frontiers in chemistry · 2026Article
- Computer-aided drug design to generate a unique antibiotic family.Nature communications · 2024Article
- Article
- Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.npj antimicrobials and resistance · 2023Review
- Collateral sensitivity: An evolutionary trade-off between antibiotic resistance mechanisms, attractive for dealing with drug-resistance crisis.Health science reports · 2023Article
- Targeting LPS biosynthesis and transport in gram-negative bacteria in the era of multi-drug resistance.Biochimica et biophysica acta. Molecular cell research · 2023Review
- Overcoming intrinsic resistance in gram-negative bacteria using small molecule adjuvants.Bioorganic & medicinal chemistry letters · 2023Review
- Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants.ACS infectious diseases · 2022Article
- Article
- High-Throughput Screen for Inhibitors ofACS omega · 2022Article
- Inhibition of LpxC Increases the Activity of Iron Chelators and Gallium Nitrate in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Essential Genes ofFrontiers in microbiology · 2021Article
- Overcoming Intrinsic and Acquired Resistance Mechanisms Associated with the Cell Wall of Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2020Review
- Dual Role ofAntimicrobial agents and chemotherapy · 2019Article
- New Treatment Options against Carbapenem-ResistantAntimicrobial agents and chemotherapy · 2019Review
- Interplay of Klebsiella pneumoniaemSphere · 2018Article
- The unusual glycine-rich C terminus of theThe Journal of biological chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LpxC inhibitors have generally shown poor in vitro activity against Acinetobacter baumannii We show that the LpxC inhibitor PF-5081090 inhibits lipid A biosynthesis, as determined by silver staining and measurements of endotoxin levels, and significantly increases cell permeability. The presence of PF-5081090 at 32 mg/liter increased susceptibility to rifampin, vancomycin, azithromycin, imipenem, and amikacin but had no effect on susceptibility to ciprofloxacin and tigecycline. Potentiating existing antibiotics with LpxC inhibitors may represent an alternative treatment strategy for multidrug-resistant A. baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.